Opioid Labeling: Congress Wants Box Warning On Immediate-Release Products
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy & Commerce Committee asks FDA to explain discrepancy in labeling between immediate release and extended release/long-acting formulations, questions effectiveness of opioid REMS.
You may also be interested in...
Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
FDA tells sponsors to revise the indication for the ER/LA analgesics to highlight appropriate patient selection rather than severity of pain and orders post-marketing studies to identify a dose and duration-of-treatment associated with higher rates of abuse, misuse, addiction, overdose and death.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.